deltatrials
Unknown NA INTERVENTIONAL 2-arm NCT04393883

A Study With Pembrolizumab for Non-small Cell Lung Cancer (NSCLC)

A Randomized, National Multicenter Clinical Study Comparing Pembrolizumab With Maintenance Therapy Every 3 Weeks and Every 6 Weeks for First-line Treatment of PD-L1 ≥1% Metastatic Non-small Cell Lung Cancer (NSCLC)

Sponsor: Beijing Sino-Japan Friendship Hospital

Conditions Non-small-lung-cell Cancer, NSCLC Pembrolizumab
Interventions A) Standard maintenance programme group, pembrolizumab 200mg, every 3 weeks, for a total of 2 years of follow-up and follow-up for 1 year; B) Improvement maintenance programme group, pembrolizumab 200mg, every 6 weeks, for a total of 2 years of follow-up and 1 year follow-up;
Updated 11 times since 2020 Last updated: Nov 27, 2020 Started: Apr 1, 2021 Primary completion: Jul 1, 2022 Completion: Jul 1, 2023
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT04393883, this NA trial focuses on Non-small-lung-cell Cancer, NSCLC and Pembrolizumab and remains ongoing. Sponsored by Beijing Sino-Japan Friendship Hospital, it has been updated 11 times since 2021, reflecting substantial change activity. This study contributes to the evolving evidence base for cancer treatment protocols.

Status Flow

~Jun 2020 – ~Dec 2020 · 6 months · monthly snapshotRecruiting~Dec 2020 – ~Jan 2021 · 31 days · monthly snapshotRecruiting~Jan 2021 – ~Oct 2021 · 9 months · monthly snapshotRecruiting~Oct 2021 – ~Nov 2022 · 13 months · monthly snapshotRecruiting~Nov 2022 – ~Aug 2023 · 9 months · monthly snapshotRecruiting~Aug 2023 – ~Jul 2024 · 11 months · monthly snapshotUnknown Status~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshotUnknown~Sep 2024 – ~Jan 2025 · 4 months · monthly snapshotUnknown~Jan 2025 – ~Apr 2025 · 3 months · monthly snapshotUnknown~Apr 2025 – ~Dec 2025 · 8 months · monthly snapshotUnknown~Dec 2025 – present · 8 months · monthly snapshotUnknown

Change History

11 versions recorded

  1. Dec 2025 — Present [monthly]

    Unknown NA

  2. Apr 2025 — Dec 2025 [monthly]

    Unknown NA

  3. Jan 2025 — Apr 2025 [monthly]

    Unknown NA

  4. Sep 2024 — Jan 2025 [monthly]

    Unknown NA

  5. Jul 2024 — Sep 2024 [monthly]

    Unknown NA

    Status: Unknown Status → Unknown

▶ Show 6 earlier versions

  1. Aug 2023 — Jul 2024 [monthly]

    Unknown Status NA

    Status: Recruiting → Unknown Status

  2. Nov 2022 — Aug 2023 [monthly]

    Recruiting NA

  3. Oct 2021 — Nov 2022 [monthly]

    Recruiting NA

  4. Jan 2021 — Oct 2021 [monthly]

    Recruiting NA

  5. Dec 2020 — Jan 2021 [monthly]

    Recruiting NA

  6. Jun 2020 — Dec 2020 [monthly]

    Recruiting NA

    First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Beijing Sino-Japan Friendship Hospital
  • Changhai Hospital of the Second Military Medical University
  • First Hospital of China Medical University
  • Guangzhou Medical University
  • Jiangsu People's Hospital
  • Qilu Hospital of Shandong University
  • Second Affiliated Hospital, School of Medicine, Zhejiang University
  • Sir Run Run Shaw Hospital
  • Southern Medical University, China
  • The Second Affiliated Hospital of Fujian Medical University
  • The Second Affiliated Hospital of the Army Medical University (the Third Military Medical University) - Xinqiao Hospital
  • Tongji Hospital
  • West China Hospital
  • Xiangya Hospital of Central South University
  • Xijing Hospital Affiliated to the Fourth Military Medical University
  • Zunyi Medical College
Data source: Second Affiliated Hospital, School of Medicine, Zhejiang University

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations